SLC5A2 and hydrops fetalis: At the time of writing, SGLT2 inhibitors are a Class 1 (i.e., strong) recommendation for human patients with reduced ejection fraction and Class 2a (i.e., moderately strong) recommendation for HF patients with mildly reduced or preserved ejection fraction.